TY - JOUR
T1 - Intravenous epoprostenol improves oxygenation index in patients with persistent pulmonary hypertension of the newborn refractory to nitric oxide
AU - Ahmad, Kaashif Aqeeb
AU - Banales, Jesse
AU - Henderson, Cody Lance
AU - Ramos, Susanne Erika
AU - Brandt, Katherine Marie
AU - Powers, George Charles
N1 - Publisher Copyright:
© 2018, Springer Nature America, Inc.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Objectives: Evaluate the short-term effects of IV epoprostenol in neonates with persistent pulmonary hypertension (PPHN) of the newborn. Study Design: We reviewed 36 patients with inhaled nitric oxide (iNO) refractory PPHN placed on IV epoprostenol from 2010 to 2015. Patients were categorized as responders or non-responders (who either died or required extracorporeal membranous oxygenation). Results: There were 15 responders and 21 non-responders. Pulmonary hypoplasia was the etiology of PPHN for 57% of non-responders vs. 13% of responders. Median oxygenation index (OI) was similar at baseline (41.8 non-responders vs. 36.5 responders, p = 0.41) with responders having a significantly lower OI by 4 h of treatment (42.3 vs. 23.1, p = 0.002). Epoprostenol responders had a median OI decrease of 11.6 within 4 h (p = 0.017) with a significant response persisting through 24 h. Conclusion: In infants with iNO-refractory PPHN, initiation of IV epoprostenol was associated with a significant and rapid OI reduction among responders.
AB - Objectives: Evaluate the short-term effects of IV epoprostenol in neonates with persistent pulmonary hypertension (PPHN) of the newborn. Study Design: We reviewed 36 patients with inhaled nitric oxide (iNO) refractory PPHN placed on IV epoprostenol from 2010 to 2015. Patients were categorized as responders or non-responders (who either died or required extracorporeal membranous oxygenation). Results: There were 15 responders and 21 non-responders. Pulmonary hypoplasia was the etiology of PPHN for 57% of non-responders vs. 13% of responders. Median oxygenation index (OI) was similar at baseline (41.8 non-responders vs. 36.5 responders, p = 0.41) with responders having a significantly lower OI by 4 h of treatment (42.3 vs. 23.1, p = 0.002). Epoprostenol responders had a median OI decrease of 11.6 within 4 h (p = 0.017) with a significant response persisting through 24 h. Conclusion: In infants with iNO-refractory PPHN, initiation of IV epoprostenol was associated with a significant and rapid OI reduction among responders.
UR - http://www.scopus.com/inward/record.url?scp=85050674272&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050674272&partnerID=8YFLogxK
U2 - 10.1038/s41372-018-0179-7
DO - 10.1038/s41372-018-0179-7
M3 - Article
C2 - 30046179
AN - SCOPUS:85050674272
SN - 0743-8346
VL - 38
SP - 1212
EP - 1219
JO - Journal of Perinatology
JF - Journal of Perinatology
IS - 9
ER -